Medtronic Completes $550M Deal for Scientia Vascular

Medtronic announced that it has completed its acquisition of Scientia Vascular, a privately-held medical device company based in Salt Lake City. The deal was valued at $550 million.

Scientia develops products to enable simplicity and access for physicians treating complex neurovascular conditions. The company’s portfolio of guidewires and catheters can be integrated with Medtronic’s suite of neurovascular products.

Its novel access platform is designed to address the challenges of highly complex and tortuous cerebral vasculature in reaching the site of an occlusion or aneurysm. Difficult access can delay delivery of therapy and impact the success of a procedure.

The deal for Scientia was first announced in March. Medtronic said the acquisition reflects its continued focus on strategic deals that bolster its leadership across core businesses.

Comments from Medtronic and Scientia

Linnea Burman, senior VP and president of Medtronic’s Neurovascular business: “The addition of Scientia’s access technologies strengthens our ability to simplify complex neurovascular procedures and support physicians with more seamless solutions. By bringing together highly complementary technologies, we are building a more integrated platform that will help advance the future of neurovascular care and enable physicians to treat more patients with greater efficiency and confidence.”

Rick Randall, CEO of Scientia: “Since its founding, Scientia has been driven by a commitment to improving patients’ lives and supporting the physicians who care for them. Joining Medtronic is an exciting next step for our team, as their Mission closely aligns with the values that have guided Scientia from the beginning. With Medtronic’s global scale, we look forward to bringing this technology to more physicians and reaching more patients around the world.”